Drug Detail

Information about Pasireotide

Generic Name	Pasireotide
IND	SOM230
Brand Name (US)
Manufacturer	Novartis
Drug Type	Somatostatin analogues
Delivery	Oral
Approval Status	Phase 3
Indications
Overall Strategy	Oncogenic Signal Path Based
Strategy	Block related tumor signal paths
Drug Category	Somatostatin receptor inhibitor

Pasireotide
A multiligand somatostatin analogue

Somatostatin is a peptide hormone expressed in many tissues throughout the body. It regulates the release of hormones such as growth hormone (GH), glucagons, insulin, gastrin, secretin, and thyroid-stimulating hormone. Somatostatin inhibitors block GH release.

The potential of somatostatin analogues as cancer therapies has recently been explored following demonstration of antineoplastic activity of these compounds in a variety of experimental models in vitro and in vivo.

Pasireotide is the next generation in somatostatin analogues. This multiligand-targeting agent is currently in late Phase II development for acromegaly and gastroentero pancreatic neuroendocrine tumors (GEP/NET), and is entering Phase III development for Cushing's disease.

Pasireotide exhibits a broad spectrum of somatostatin receptor activation. Compared with octreotide in vitro, pasireotide has far higher binding affinity for sst-1, sst-3, and sst-5 receptors (30, 5, and 40 times, respectively), and a comparable affinity for sst-2 receptors.